Sugi Predict

Sugi Predict / Compounds / SCHEMBL1269672

SCHEMBL1269672

SCHEMBL1269672

O=C(O)CCc1nc2ccccc2s1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.82
▸ ALOX15 P16050 1/20 0.82
▸ HTT P42858 1/20 0.82
▸ HPGD P15428 4/20 0.75
▸ RAB9A P51151 1/20 0.75
▸ MAPK1 P28482 2/20 0.66
▸ L3MBTL1 Q9Y468 2/20 0.66
▸ GAA P10253 1/20 0.66
▸ HDAC6 Q9UBN7 2/20 0.66
▸ ALDH1A1 P00352 4/20 0.63
▸ MAPT P10636 4/20 0.63
▸ SLC13A5 Q86YT5 1/20 0.62
▸ LMNA P02545 1/20 0.62
▸ KMT2A Q03164 4/20 0.61
▸ POLB P06746 4/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ ATM Q13315 1/20 0.59
▸ TSHR P16473 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL243430 0.90 SMN1; SMN2 (1.00) SMN1; SMN2ALOX15HTTHPGDRAB9A
SCHEMBL6645560 0.89 SMN1; SMN2 (0.91) SMN1; SMN2ALOX15HTTHPGDRAB9A
SCHEMBL27984502 0.88 HPGD (0.72) SMN1; SMN2ALOX15HTTHPGDRAB9A
SCHEMBL7835431 0.88 SMN1; SMN2 (0.89) SMN1; SMN2ALOX15HTTHPGDRAB9A
SCHEMBL7835167 0.88 SMN1; SMN2 (0.89) SMN1; SMN2ALOX15HTTHPGDRAB9A
Methane SCHEMBL7997331 0.86 SMN1; SMN2 (0.86) SMN1; SMN2ALOX15HTTHPGDRAB9A
SCHEMBL8821050 0.85 HPGD (0.68) SMN1; SMN2ALOX15HTTHPGDRAB9A
SCHEMBL5212645 0.85 HPGD (0.68) SMN1; SMN2ALOX15HTTHPGDRAB9A
SCHEMBL11590976 0.85 HPGD (0.68) SMN1; SMN2ALOX15HTTHPGDRAB9A
SCHEMBL3060261 0.83 HPGD (0.66) SMN1; SMN2ALOX15HTTHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619388-A1 CATHEPSIN L INHIBITORS Biofront Therapeutics (Beijing) Co., Ltd. (CN) 2025-09-24 — — EP disclosed
WO-2025125829-A1 NORA INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2025-06-19 — — WO disclosed
WO-2024140356-A1 CATHEPSIN L INHIBITORS BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) 2024-07-04 — — WO disclosed
CN-107709323-B Hydroxyl purine compound and application thereof 广东众生睿创生物科技有限公司 2020-11-20 — — CN disclosed
US-10278973-B2 Hydroxyl purine compounds and use thereof Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-05-07 — — US disclosed
US-10278973-B2 Hydroxyl purine compounds and use thereof Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-05-07 — — US disclosed
US-10144732-B2 ATX modulating agents BIOGEN MA INC. (US) 2018-12-04 — — US disclosed
US-20180140607-A1 HYDROXYL PURINE COMPOUNDS AND USE THEREOF Guangdong Raynovent Biotech Co., Ltd. (CN) 2018-05-24 — — US disclosed
EP-3299371-A1 HYDROXYL PURINE COMPOUNDS AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-28 — — EP disclosed
EP-3266783-A1 DERIVATIVES OF AZA ADAMANTANES AND USES THEREOF Connexios Life Sciences Pvt. Ltd. (IN) 2018-01-10 — — EP disclosed
US-20050215495-A1 Macrolide antibiotics ALIHODZIC SULEJMAN 2005-09-29 — — US disclosed
CN-1192021-C 3-azabicyclo [3.1.0] hexane derivatives as opioid receptor ligands PFIZER LTD (US) 2005-03-09 — — CN disclosed
CN-1492874-A Macrolide antibiotics — 2004-04-28 — — CN disclosed
US-20030013875-A1 3-azabicyclo[3.1.0]hexane derivatives useful in therapy PFIZER, INC. (US) 2003-01-16 — — US disclosed
US-20020072616-A1 3-azabicyclo[3.1.0]hexane derivatives useful in therapy PFIZER INC. 2002-06-13 — — US disclosed
CN-1331679-A 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands PFIZER LTD (US) 2002-01-16 — — CN disclosed
US-6313312-B1 OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING PFIZER INC 2001-11-06 — — US disclosed
EP-1140828-A1 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS Pfizer Limited (GB) 2001-10-10 — — EP disclosed
WO-2000069827-A1 HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES DARWIN DISCOVERY LIMITED (GB) 2000-11-23 — — WO disclosed
WO-2000039089-A1 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS PFIZER LIMITED (GB) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072616-A1 3-azabicyclo[3.1.0]hexane derivatives useful in therapy OPRM1, OPRK1, OPRD1 SMN1; SMN2 2757/4885ALOX15 165/4885HTT 3133/4885
US-20050215495-A1 Macrolide antibiotics IL1R1, MRPL12, RPS21 SMN1; SMN2 3554/4885ALOX15 2590/4885HTT 3482/4885
US-20180140607-A1 HYDROXYL PURINE COMPOUNDS AND USE THEREOF PNP, PDE7A, PDE2A SMN1; SMN2 1786/4885ALOX15 1143/4885HTT 2349/4885
US-10278973-B2 Hydroxyl purine compounds and use thereof PNP, PDE7A, PDE2A SMN1; SMN2 1786/4885ALOX15 1143/4885HTT 2349/4885
US-10144732-B2 ATX modulating agents ENPP2, ATXN10, ATXN2 SMN1; SMN2 119/4885ALOX15 2546/4885HTT 89/4885
US-20030013875-A1 3-azabicyclo[3.1.0]hexane derivatives useful in therapy OPRM1, OPRK1, OPRD1 SMN1; SMN2 2757/4885ALOX15 165/4885HTT 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.